The team at KDAH have recently been approved for Pancreas and Small Bowel Transplant and are listing patients for both.
Type 1 diabetes mellitus afflicts the lives of millions of Indians. Type 1 diabetes usually is diagnosed in children and young adults, leading to the term "juvenile diabetes." The more common form of diabetes is type 2 diabetes, also known as "adult-onset diabetes." In both forms of diabetes, the body is unable to keep the blood sugar levels under proper control. High blood sugar levels can damage many parts of the body. Patients with diabetes often suffer from kidney failure, blindness, nerve problems, hardening of the arteries and other problems because the blood sugar is too high.
The pancreas gland makes insulin, but also has many other functions. Most of the pancreas gland makes juices that help digest food. Doctors now know that special cells found within the islets, called beta cells, make the hormone insulin that keeps the blood sugar under proper control. In type 1 diabetes, doctors think the patients own immune system destroys the beta cells. All patients with type 1 diabetes need insulin shots to keep the blood sugar under control, leading to the common name "insulin dependent diabetes."
Transplantation is well suited to the treatment of type 1 diabetes. The transplant provides the recipient with replacement beta cells. Transplantation of the whole pancreas gland now provides many type 1 patients with freedom from insulin treatment. Transplantation of only the islets after separating them from the rest of the pancreas is under study.
Type 2 diabetes is different. Type 2 diabetes has many causes. Diet, weight loss and exercise can often help type 2 patients get their blood sugars under control. If the blood sugars are still too high, medications can often help. If none of these treatments helps keep the blood sugar under control, then patients with type 2 diabetes may need insulin shots. Even though some patients with type 2 diabetes may eventually need insulin shots, many refer to type 2 diabetes as "non-insulin dependent diabetes." Although doctors are now finding type 2 diabetes in teenagers, the onset of this disease usually occurs in adults, leading to the other common name of "adult-onset diabetes." Doctors know that insulin resistance characterizes type 2 diabetes, meaning that the body does not use the insulin produced by the beta cells normally. Eventually the beta cells in type 2 patients may wear out from overworking.
In summary, a lack of insulin producing beta cells causes type 1 diabetes (also known as juvenile-onset or insulin-dependent diabetes mellitus), and replacement of the beta cells through transplantation is the only current treatment that provides freedom from insulin therapy. Insulin resistance characterizes type 2 diabetes (also known as adult onset or non-insulin-dependent diabetes mellitus), and transplantation is an accepted treatment option for these patients
The clinical practice recommendations of the American Diabetes Association state that a pancreas transplant (Simultaneous Kidney and Pancreas Transplant [SPK] or Pancreas After Kidney Transplant [PAK] is an acceptable surgical procedure in type 1 diabetic patients also undergoing kidney transplantation. These must be in medically suitable type 1 diabetic patient who are also renal transplant candidates or who have excellent function of a kidney transplant who is interested in receiving a pancreas transplant. The vast majority of pancreas transplants are performed as an SPK followed by PAK.
Pancreas transplantation alone [PTA] should be performed before secondary complications of diabetes become irreversible and before the need for a kidney transplant. A creatinine clearance above 60 to 70 mL/min is usually required as immunosuppressant can cause accelerated deterioration of native renal function in patients with a lower creatinine clearance.
There are three groups of patients that are considered for pancreas transplantation. First is the simultaneous kidney and pancreas transplantation (or SPK) for diabetics who are in renal failure. This is generally the preferred method of pancreas transplantation having the advantage of only one surgical intervention and one source of foreign antigen for the recipient patient.
Second is pancreas after kidney transplant (or PAK) for diabetic patients who already have a functioning kidney allograft. Immunosuppressive therapy is not a major concern as patients are already immunosuppressed for their kidney allograft. The main risk to the patient is the alteration in immunosuppression necessary after pancreas transplantation and the inherent risks of an intra abdominal surgical procedure. In general, type 1 diabetic patients undergoing living or cadaveric renal transplantation should have their kidney placed on the left side in anticipation of a pancreas transplant in the future.
Third is the pancreas transplantation alone (or PTA). This is a therapeutic option of the pre uremic patient with none to minimal renal dysfunction who has brittle diabetic management despite the administration of conventional anti diabetic therapies and hypoglycemic unawareness. The main risks to these patients are the long-term effects of chronic immunosuppression and the surgical procedure itself.
This section is for patients with diabetes who are considering a combined kidney Pancreas transplant or a pancreas only transplant.
The pancreas is an organ inside the abdomen, which consists of 2 different types of tissue with 2 separate functions. Most of the pancreas is a gland that secretes a fluid rich in digestive enzymes. This helps digestion of the food we eat. About 2-3% of the pancreas consists of endocrine tissue, which is a cluster of cells (islets) that secretes small amounts of hormones into the bloodstream. The most important one amongst these hormones is insulin. The lack of insulin causes diabetes. Pancreas transplants are performed to treat diabetes.
No. Only patients suffering from the so-called type I diabetes mellitus lack insulin as a result of self-destruction of their insulin producing islets. Such patients can be given a further source of islets by pancreas transplantation. Type II diabetes is much more common. In this disease the problem is not lack of insulin, but a resistance to the action of insulin on other tissues. Some patients with type II diabetes may require insulin injections later during the course of their disease. Pancreas transplantation is only suitable for patients with type I diabetes and a selected few with type 2 disease.
People with type I diabetes require lifelong treatment with regular injections of insulin (usually a few times each day). Pancreas transplantation is the only treatment for diabetes that can restore complete insulin independence and normal blood sugar levels. Patients after successful pancreas transplantation do not need insulin, have no special dietary requirements, do not need to pierce themselves regularly to check their blood sugar levels and are not at any risk of becoming hypoglycemic.
It is also known that most of the complications of diabetes are related to blood sugar control such as:
Strict and good blood sugar control in diabetic patients is associated with a delay in the onset and a reduction in the severity of complications and perhaps even prevention of some complications. Since there is no better means of blood sugar control than successful pancreas transplantation, this operation should benefit Diabetic patients by preventing or helping some of the long-term complications of diabetes.
There is a substantial amount of convincing indirect evidence about the potential influence of successful pancreas transplantation on long-term diabetic complications. We can say with a reasonable degree of confidence that successful pancreas transplantation will prevent or even reverse early changes of diabetic nephropathy such that diabetic patients will not continue to develop end stage kidney failure and require dialysis. There is also reasonably good evidence showing that successful pancreas transplantation can prevent or partially reverse diabetic neuropathy.
The amount of benefit that one can expect from the pancreas transplant depends on when exactly the transplant is performed in the course of the disease. End stage retinopathy with blindness or significant neuropathy and vascular disease, which may have necessitated amputation, clearly represent very advanced and irreversible complications, which cannot be improved by pancreas transplantation.
Almost all studies have shown better long-term survival in diabetic patients who have been treated with pancreas transplantation compared with those who have been treated with insulin. It may be that younger and fitter diabetic patients receive pancreas transplants whereas older diabetics with other health problems are those who remain on insulin. Better long-term survival rates with pancreas transplantation could therefore be simply a reflection of patient selection. However more recent data in the scientific literature suggests that pancreas transplantation does confer a genuine survival advantage to diabetic patients. This is probably related to the influence of pancreas transplantation on long-term diabetic complications. Five or 10 years after transplantation the difference in the survival prospects for patients with transplants is considerably different to those who remain on insulin.
Mainly because it has risks. Lifelong treatment with insulin injections is still safer for most patients with type I diabetes. Even if pancreas transplantation could be made much safer, there would be the problem of shortage of organ donors to provide the number of pancreas transplants that we need to perform to meet the demand.
Transplantation of the pancreas involves a major operation. Like all surgical procedures this puts the patient at risk of complications and even a small chance of death. Recent advances in surgical techniques and other medications that are used have greatly improved the safety of the pancreas transplant operation, such that around 97-98% of patients undergoing pancreas transplants will survive.
Other complications such as bleeding and infection are not rare and about 1 in 4 patients undergoing a pancreas transplant will require at least 1 more operation to deal with complications. Other risks relate to the medication that patients need to use after transplantation.
Pancreas transplants like other organ transplants involve transfer of foreign tissue, which would undergo rejection in normal circumstances. It is therefore necessary to use medication to suppress the immune system in order to prevent the rejection of the transplanted organs. These medicines (immunosuppressant) have many potentially serious side effects such as increased risk of infection and even a small increase in the probability of developing cancer.
The success rate expressed as the probability of being cured of diabetes (not needing any insulin) 1 year after the transplant is about 85%. This is similar to the success rate of other organ transplants such as kidney, liver or heart transplants. In the longer-term (beyond 1 year) patients with pancreas transplants are likely to do at least as well as those with other types of organ transplants.
Yes. In fact if a diabetic patient requires a kidney transplant in order to treat kidney failure, they can also be given a pancreas transplant at the same time. This type of double transplant (simultaneous pancreas kidney transplant) is particularly attractive since patients have already been selected for one transplant, which requires immunosuppression. With only minimal additional risk it is possible to treat diabetes as well as treating kidney failure.
Yes they can, but this will be appropriate in only a very small proportion of diabetic patients. As discussed above, for most diabetic patients without kidney failure lifelong treatment with insulin, despite its problems and the inconvenience, is still safer than a pancreas transplant. However a small number of diabetic patients have life threatening complications of diabetes (for example hypoglycemic unawareness). In such patients benefits of a pancreas transplant outweigh the risks, indeed a pancreas transplant can be life saving.
Insulin producing cells make up only around 2% of the pancreas gland. If these islets could be separated from the remainder of the pancreas gland they could be transplanted with a very simple procedure similar to a blood transfusion. This has been tried for many years without much success for various technical reasons. We are making progress and only in the past year or so a small number of patients have received successful islet transplants. This is obviously attractive because the surgical risks of a major operation can be avoided. However even then patients receiving islet transplants do require lifelong immunosuppressive medication with potentially serious side effects.
Difficult to know. Problems with islet transplantation are profound and it is not yet a common successful procedure. We are making some progress but at least for the foreseeable future, the only realistic option to make diabetic patients independent of insulin will still be a pancreas transplant.
This depends on each individual patient and how they recover from their operation and how well the organs function. It is usually around 14 – 21 days.
In the early weeks after a transplant, there is a need to review patients at the out-patients clinic very frequently. Therefore even if all goes very well, return to work is not practical before 2 months. Most patients will be off work for about three months, some longer.
If the pancreas functions well you will not need any insulin after your operation and your blood sugar will be normal.
The team consists of Endocrinologist, Nephrologist, Kidney Surgeons and Pancreas Transplant Surgeons.